Robaxin and Chronic kidney disease - a phase IV clinical study of FDA data
Chronic kidney disease is found among people who take Robaxin, especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months.
The phase IV clinical study analyzes which people take Robaxin and have Chronic kidney disease. It is created by eHealthMe based on reports of 7,061 people who have side effects when taking Robaxin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
7,061 people reported to have side effects when taking Robaxin.
Among them, 136 people (1.93%) have Chronic kidney disease.
What is Robaxin?
Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 7,879 Robaxin users for its effectiveness, alternative drugs and more.
What is Chronic kidney disease?
Chronic kidney disease is found to be associated with 2,090 drugs and 1,043 conditions by eHealthMe.
Number of Robaxin and Chronic kidney disease reports submitted per year:
Time on Robaxin when people have Chronic kidney disease *:
Gender of people who have Chronic kidney disease when taking Robaxin*:
Age of people who have Chronic kidney disease when taking Robaxin *:
Common drugs people take besides Robaxin *:
Common side effects people have besides Chronic kidney disease *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Robaxin and have Chronic kidney disease?Check whether Chronic kidney disease is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Aalaei-Andabili, S. H., Umer, M., & Keeley, E. C., "An Adult Woman With Stage 4 Chronic Kidney Disease and a Diffuse Rash", JAMA cardiology, 2019 Jan .
Alternative drugs to, pros and cons of Robaxin:
- Robaxin (7,879 reports)
Chronic kidney disease treatments and more:
- Chronic kidney disease (116,658 reports)
COVID vaccines that are related to Chronic kidney disease:
- Chronic kidney disease in Moderna COVID Vaccine
- Chronic kidney disease in Pfizer BioNTech Covid Vaccine
- Chronic kidney disease in Johnson and Johnson Covid Vaccine
How severe was Chronic kidney disease and when was it recovered:
Expand to all the drugs that have ingredients of methocarbamol:
Common drugs associated with Chronic kidney disease:
All the drugs that are associated with Chronic kidney disease:
- Chronic kidney disease (2,090 drugs)
Common conditions associated with Chronic kidney disease:
All the conditions that are associated with Chronic kidney disease:
- Chronic kidney disease (1,043 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Robaxin) and Robaxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.